Scanfil and Profound Medical Start Cooperation

torstai 20.12.2018

Press Release
20 December 2018

Scanfil and Profound Medical Start Cooperation

Scanfil Plc., a Global Contract Manufacturer and Systems Supplier, has signed an agreement with Profound Medical Corp., a medical technology company focused on a therapeutics platform that provides the precision of real-time Magnetic Resonance Imaging combined with the safety and ablation power of directional and focused ultrasound technology for the incision-free ablation of diseased tissue.

Scanfil was selected due to its broad service offering and its capability to serve the customer throughout the whole life-cycle of the product. Scanfil will be part of making Profound’s revolutionary new cancer treatment equipment, which combines MRI and ultrasound for better and more precise treatment.

“Securing a reliable and experienced manufacturer is crucial as we expect interest in, and adoption of, our technology to grow in 2019 and beyond,” said Arun Menawat, Profound’s CEO. “We are looking forward to working with Scanfil as we continue to pursue growth opportunities for our products, which we believe could fulfill unmet needs of doctors and patients alike.”

“I am happy that Profound Medical selected us to be their long-term partner. The company is very interesting, and their products are extremely innovative. We were selected due to our vertical integration service concept and capability to master material management, electronics and sheet metal manufacturing, final integration, testing, etc. This is again a good example that our strategy in the contract manufacturing market is right for us and it works”, says Timo Sonninen, Vice President, Sales.

Scanfil has over 40 years of successful experience in serving global companies within, e.g., MedTech& Life Science & Environment, Energy & Automation, Communication and Urban Applications.

Scanfil Plc

Timo Sonninen
Vice President, Sales

About Profound Medical Corp.
Profound is developing and commercializing therapeutic platforms that combine the power of real-time magnetic resonance (MR) imaging and non-invasive ultrasound ablation. These key technology pillars, linked with intelligent software and robotics, have the potential to fulfill unmet needs of patients and clinicians in many anatomies and disease states, including prostate disease (localized prostate cancer and benign prostatic hyperplasia), uterine fibroids, and bone metastases. Profound mission is to “profoundly” change the standard of care whereby clinicians can confidently ablate tissue with precision, and patients can access safe and effective treatment options and quickly return to their daily lives.

Profound’s novel TULSA-PRO® system combines real-time MR imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control. TULSA-PRO® is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects. TULSA-PRO® is CE marked and is undergoing a pilot commercial launch in key European and other CE mark jurisdictions. Profound is also sponsoring a multicenter, prospective U.S. Food and Drug Administration (FDA)-registered clinical trial, TACT, which if successful, is expected to support its application to the FDA for clearance to market TULSA-PRO® in the United States.

Profound is also commercializing Sonalleve®, an innovative therapeutic platform that combines real-time MR imaging and thermometry with thermal ultrasound to enable precise and incision-free ablation of diseased tissue. Sonalleve® is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. The technology was also recently approved by the Chinese Food and Drug Administration for the non-invasive treatment of uterine fibroids. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve®, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy, where the technology has been shown to have clinical application.

Scanfil Plc
Scanfil is an international contract manufacturer and system supplier for the electronics industry with 40 years of experience in demanding contract manufacturing. Scanfil provides its customers with an extensive array of services, ranging from product design to product manufacturing, material procurement and logistics solutions. Vertically integrated production and a comprehensive supply chain are the foundation of Scanfil’s competitive advantages: speed, flexibility and reliability.

Typical Scanfil products include mobile and communications network devices, automation system modules, frequency converters, lift control systems, analysers, various slot and vending machines, and devices related to medical technology and meteorology. Scanfil services are used by numerous international automation, energy, IT and health service providers, as well as companies operating in the field of urbanisation. Scanfil’s network of factories consists of 10 production units in Europe, Asia and North America. The total number of employees is about 3,400.

Takaisin

Invest to the
future growth

Latest